Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
Listen to expert commentary on emerging strategies in clinical trial development for treating patients with myelofibrosis, with a focus on alternatives to JAK inhibitors.
Decera Clinical Education Oncology Podcast · Jacqueline S Garcia MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:
- Navitoclax (BCL-XL/BCL-2 inhibitor)
- Pelabresib (BET inhibitor)
- Imetelstat (telomerase inhibitor)
- Luspatercept (erythroid maturation agent)
- Additional strategies
Presenter:
Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Link to the full program here. https://bit.ly/47z8WCV
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.